Pharmacoeconomic ABC- and VEN- analyses of treatment of community -acquired pneumonia patients with comorbidities

Abstract

The estimation of economic rationality treatment costs of community-acquired pneumonia patients with comorbidities was performed using ABC- and VEN-analyses. It was established financial resources use is partial rational, because most of expenses are used for vital medicines, but non-essential pathogenical drugs for treatment of CAP patients with comorbidities are included into group. These medicines increase treatment cost in average 108,5 UHR/patient without improvement of clinical effectiveness of therapy.